Cell therapy (Stem-cell derived) · Kills target cells, directed at B-cell maturation antigen (BCMA) (TNFRSF17) · developed by Fate Therapeutics
FT576 is an allogeneic natural killer cell therapy derived from a clonal, CD38-knockout induced pluripotent stem cell line. The cells express a anti-BCMA chimeric antigen receptor, a high-affinity non-cleavable CD16 and an IL-15/IL-15 receptor fusion protein. It is being studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05182073 | Phase 1 | Multiple Myeloma | Completed | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple MyelomaMyeloma
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →